Key Takeaways
- • Peli BioThermal acquired Evo from BioLife Solutions, adding cryogenic shippers and the evoIS® technology platform to strengthen its cold chain logistics portfolio (announcement date: October 7, 2025).
- • The Evo acquisition directly addresses the Cell and Gene Therapy (C>) sector, where cryogenic transport precision and reliability are critical for therapy delivery and patient outcomes.
- • Peli BioThermal gains access to Evo's existing customer base while offering those users integration benefits and direct sourcing through the expanded platform; conversely, Evo products will benefit from Peli's global service network and accelerated development resources.
- • The strategic acquisition expands Peli BioThermal's reach into new pharmaceutical and biopharmaceutical markets while consolidating its position as a comprehensive cold chain solutions provider across the pharmaceutical value chain.
Summary
Peli BioThermal announced on October 7, 2025, its acquisition of Evo from BioLife Solutions, a transaction designed to strengthen its portfolio of temperature-controlled logistics solutions and expand its market presence in the rapidly expanding Cell and Gene Therapy sector. The Evo portfolio includes cryogenic shippers and the proprietary evoIS® technology platform, both engineered to meet the stringent requirements of C> transport, where precision, reliability, and flexibility directly impact the delivery of life-saving cellular and gene therapies to patients.
According to Sam Herbert, CEO of Peli BioThermal, the acquisition represents "a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers' toughest cold chain challenges." The deal creates a more integrated ecosystem for existing Peli BioThermal customers, who will gain expanded product choices and convenience through consolidated sourcing, while Evo's current user base will benefit from access to Peli BioThermal's global expertise, service infrastructure, and accelerated product development capabilities.
The transaction strengthens Peli BioThermal's ability to deliver a comprehensive range of cold chain solutions across the pharmaceutical value chain, positioning the company to engage with a broader customer base encompassing pharmaceutical, biopharmaceutical, and clinical supply organizations. The Evo product line is expected to benefit from accelerated innovation and scale as part of the larger organization, creating enhanced value for the combined customer base. The acquisition is particularly significant given the growth trajectory and specialized requirements of the Cell and Gene Therapy market, where cryogenic transport solutions remain essential infrastructure for advancing therapeutic innovation and patient access.
According to Sam Herbert, CEO of Peli BioThermal, the acquisition represents "a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers' toughest cold chain challenges." The deal creates a more integrated ecosystem for existing Peli BioThermal customers, who will gain expanded product choices and convenience through consolidated sourcing, while Evo's current user base will benefit from access to Peli BioThermal's global expertise, service infrastructure, and accelerated product development capabilities.
The transaction strengthens Peli BioThermal's ability to deliver a comprehensive range of cold chain solutions across the pharmaceutical value chain, positioning the company to engage with a broader customer base encompassing pharmaceutical, biopharmaceutical, and clinical supply organizations. The Evo product line is expected to benefit from accelerated innovation and scale as part of the larger organization, creating enhanced value for the combined customer base. The acquisition is particularly significant given the growth trajectory and specialized requirements of the Cell and Gene Therapy market, where cryogenic transport solutions remain essential infrastructure for advancing therapeutic innovation and patient access.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.